FDA Gets Practical On Follow-On Biologics As Pathway Remains Theoretical
Executive Summary
Although a pathway for follow-on biologics has not been established by Congress, FDA is offering industry a description of what some of the paving stones could look like
You may also be interested in...
Follow-On Biologics Is Pathway Not Taken, But House Cmte. Talks Continue
Energy and Commerce Health subcommittee members agreed Oct. 31 that there is not enough time left this session to pursue legislation addressing follow-on biologics
Follow-On Biologics Is Pathway Not Taken, But House Cmte. Talks Continue
Energy and Commerce Health subcommittee members agreed Oct. 31 that there is not enough time left this session to pursue legislation addressing follow-on biologics
FDA Sees Critical Path Opportunity To Address Follow-On Biologics
FDA's Critical Path opportunities list suggests that the agency is actively working to lay the scientific groundwork for follow-on biologics